Literature DB >> 3345949

Recurrent disease after negative second-look laparotomy in stages III and IV ovarian carcinoma.

K C Podratz1, G D Malkasian, H S Wieand, S S Cha, R A Lee, C R Stanhope, T J Williams.   

Abstract

Between 1977 and 1984, second-look laparotomy to evaluate disease status after adjuvant chemotherapy was performed in 134 patients originally presenting with advanced epithelial ovarian carcinoma. Surgical and histologic assessment did not detect persistent disease in 50 patients (37%). Recurrent carcinoma was subsequently documented in 15 patients (30%), all failures occurring within the abdominal cavity or the retroperitoneal space. Several patient subgroups at high risk for recurrence after negative second-look laparotomy are identified that might benefit from additional adjunctive therapy. Because of different treatment-associated morbidities, the corresponding sensitivities and specificities of the high-risk groups may assist subsequent treatment selection.

Entities:  

Mesh:

Year:  1988        PMID: 3345949     DOI: 10.1016/0090-8258(88)90226-0

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  8 in total

Review 1.  Second-look laparotomy for epithelial ovarian cancer: a reappraisal.

Authors:  C S Chu; S C Rubin
Journal:  Curr Oncol Rep       Date:  2001-01       Impact factor: 5.075

2.  Preclinical evaluation of Mab CC188 for ovarian cancer imaging.

Authors:  M Xu; M P Rettig; G Sudlow; B Wang; W J Akers; D Cao; D G Mutch; J F DiPersio; S Achilefu
Journal:  Int J Cancer       Date:  2012-01-11       Impact factor: 7.396

Review 3.  Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis.

Authors:  Hassan-Alaa-Hammed Al-Shammaa; Yan Li; Yutaka Yonemura
Journal:  World J Gastroenterol       Date:  2008-02-28       Impact factor: 5.742

4.  Surgical second-look in epithelial ovarian cancer: high recurrence rate after negative results and lack of survival benefit limits its role in standard management.

Authors:  Salih Taşkın; Mete Güngör; Elif Aylin Taşkın; Fırat Ortaç
Journal:  J Turk Ger Gynecol Assoc       Date:  2011-03-01

Review 5.  The roles of second-look laparotomy and cancer antigen 125 in the management of ovarian carcinoma.

Authors:  A E Selman; L J Copeland
Journal:  Curr Oncol Rep       Date:  1999-09       Impact factor: 5.075

Review 6.  Ovarian cancer: the clinical role of US, CT, and MRI.

Authors:  Kaori Togashi
Journal:  Eur Radiol       Date:  2003-12       Impact factor: 5.315

7.  Hexamethylmelamine as consolidation treatment for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy.

Authors:  Yong Soon Kwon; Joo-Hyun Nam; Dae-Yeon Kim; Dae-Shik Suh; Jong-Hyeok Kim; Yong Man Kim; Young Tak Kim
Journal:  J Korean Med Sci       Date:  2009-07-30       Impact factor: 2.153

8.  Systematic lymphadenectomy in ovarian cancer at second-look surgery: a randomised clinical trial.

Authors:  T Dell' Anna; M Signorelli; P Benedetti-Panici; A Maggioni; R Fossati; R Fruscio; R Milani; L Bocciolone; A Buda; C Mangioni; G Scambia; R Angioli; E Campagnutta; R Grassi; F Landoni
Journal:  Br J Cancer       Date:  2012-08-02       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.